相关实验视频
Updated: Jun 23, 2025

Basophil Activation Test for Allergy Diagnosis
Published on: May 31, 2021
在慢性诱导性疹的主要亚型中揭示治疗反应预测因素
Sinem Ornek Ozdemir1, Pelin Kuteyla Can2, Ece Nur Degirmentepe3
1Department of Dermatology, Health Sciences University, Ankara Training and Research Hospital, Ankara, Turkey, drsinemornek@yahoo.com.
慢性诱导性疹 (CIndU) 对抗组胺剂 (AHs) 和奥马利祖马布 (omalizumab) 的反应良好. 疾病持续时间和血管等因素可以预测CIndU患者的AH治疗结果.
科学领域:
- 免疫学 免疫学 免疫学
- 皮肤病学 皮肤病学
- 过敏 过敏是一种过敏.
背景情况:
- 慢性诱导性疹 (CIndU) 是由特定因素引发的慢性疹 (CU) 的一个子集.
- 关于CIndU亚型的治疗响应率和预测指标的数据有限.
研究的目的:
- 评估常见的CIndU亚型中的抗组胺 (AH) 和奥马利祖马布反应率.
- 在CIndU中识别治疗反应的预测因素.
主要方法:
- 对423名具有至少一个CIndU亚型的CU患者的回顾性分析.
- 在CIndU和慢性自发性疹 (CSU) 以及CIndU子组之间比较治疗反应.
主要成果:
- CIndU反应率:51.6% (标准AHs),51.5% (升剂/联合AHs),86.5% (奥马利祖马布).
- 在CIndU与CSU加CIndU (78.3%与62%) 和在症状性皮肤学 (SD) 和冷 (ColdU) 与胆性 (ChoU) 中,AH反应更高.
- 预测AH不响应的预测因素包括较长的疾病持续时间,血管,共存的CSU,混合的CIndU亚型,以及较低的基线疹控制测试 (UCT) 分数.
结论:
- CIndU对AHs和omalizumab的治疗反应良好.
- 在SD和ColdU中,AH反应比ChoU更好.
- 疾病持续时间,血管,伴随的CSU,混合CIndU和低UCT得分可以预测AH治疗结果.
更多相关视频
03:40Acupoint Catgut Embedding Therapy in Traditional Chinese Medicine for Managing Allergic Rhinitis
Published on: December 20, 2024
06:34A Component-resolved Diagnostic Approach for a Study on Grass Pollen Allergens in Chinese Southerners with Allergic Rhinitis and/or Asthma
Published on: June 4, 2017
相关概念视频
Hypersensitivities
Types of Hypersensitivities
Hypersensitivity reactions are categorized into four types: Type 1, Type 2, Type 3, and Type 4. Each type has a distinct mechanism...
Allergic Drug Reactions
Allergic Reactions
Desensitization and Tachyphylaxis
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Antiasthma Drugs: Leukotriene Modifiers
Leukotriene modifiers work through two distinct mechanisms: